comscoreKisqali in Combination With Hormonal Therapy and Ovarian Suppression Effective Treatment for Metastatic Hormone-Receptor-Positive, HER2-Negative Disease in Premenopausal Women: 2017 SABCS

Kisqali in Combination With Hormonal Therapy and Ovarian Suppression Effective Treatment for Metastatic Hormone-Receptor-Positive, HER2-Negative Disease in Premenopausal Women: 2017 SABCS

Debu Tripathy, MD, discusses the results of the study he presented on treating premenopausal women with Kisqali.
Apr 9, 2019
00:00
Download
00:00

The targeted therapy Kisqali (chemical name: ribociclib) is approved to be used in combination with an aromatase inhibitor to treat advanced-stage or metastatic hormone-receptor-positive, HER2-negative breast cancer that hasn’t been treated with hormonal therapy yet in postmenopausal women. Dr. Debu Tripathy discusses the results of the MONALEESA-7 study he presented at the 2017 San Antonio Breast Cancer Symposium showing that Kisqali can help treat premenopausal and perimenopausal women diagnosed with the same type of breast cancer.

Listen to the podcast to hear Dr. Tripathy explain:

  • why the study is important

  • why ovarian suppression helps make the treatments more effective

  • the side effects caused by Kisqali

  • why he thinks this study will change practice

Editor's Note: On April 4, 2019, the FDA expanded the use of Ibrance so the medicine now can be used to treat men diagnosed with advanced-stage or metastatic hormone-receptor-positive, HER2-negative breast cancer.

About the guest
 
Debu Tripathy, MD

Dr. Debu Tripathy is a professor of medicine and chairperson of the
Department of Breast Medical Oncology at the University of Texas MD
Anderson Cancer Center.

— Last updated on May 2, 2022, 5:42 PM

 
Lilly Oncology

This content made possible by Lilly Oncology.

 
 
Support Breastcancer.org to produce more content like this

Your donation goes directly to what you read, hear, and see on Breastcancer.org.

Donate